<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34322897</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>An open label pilot study of the safety and tolerability of perampanel in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>504</StartPage><EndPage>508</EndPage><MedlinePgn>504-508</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27385</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS">Perampanel, a selective noncompetitive &#x3b1;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonist, is capable of slowing the progression of the amyotrophic lateral sclerosis (ALS) phenotype and increasing the number of anterior horn cells in transgenic mice. Trials of perampanel in epilepsy showed a favorable tolerability profile. In this study we aimed to determine the tolerability and safety of perampanel in patients with ALS.</AbstractText><AbstractText Label="METHODS">Enrolled subjects were started on 2&#xa0;mg/day of perampanel and the dose was increased by 2&#xa0;mg/day every week to a maximum dose of 8&#xa0;mg/day. Our primary outcome measure was tolerability, which was evaluated by monitoring adverse events. The secondary outcome measure was clinical progression, assessed using the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) and spirometry.</AbstractText><AbstractText Label="RESULTS">Six participants were enrolled. All had adverse events, mostly behavioral. Two completed the trial and the other four withdrew due to adverse events. All participants reported resolution of these events after discontinuation of the drug. The trial was halted due to the large number of adverse events.</AbstractText><AbstractText Label="DISCUSSION">The use of perampanel in this study of ALS was limited by its poor tolerability.</AbstractText><CopyrightInformation>&#xa9; 2021 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hotait</LastName><ForeName>Mostafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>Helen H</ForeName><Initials>HH</Initials><Identifier Source="ORCID">0000-0002-0211-1834</Identifier><AffiliationInfo><Affiliation>Department of Neurology, American University of Beirut medical Center, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saab</LastName><ForeName>Georges E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Department of Neurology, American University of Beirut medical Center, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salameh</LastName><ForeName>Johnny S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurology, American University of Beirut medical Center, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009570">Nitriles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011728">Pyridones</NameOfSubstance></Chemical><Chemical><RegistryNumber>H821664NPK</RegistryNumber><NameOfSubstance UI="C551441">perampanel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000066553" MajorTopicYN="N">Problem Behavior</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011728" MajorTopicYN="N">Pyridones</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077260" MajorTopicYN="Y">Sleepiness</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adverse events</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">perampanel</Keyword><Keyword MajorTopicYN="N">safety</Keyword><Keyword MajorTopicYN="N">tolerability</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>29</Day><Hour>7</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34322897</ArticleId><ArticleId IdType="doi">10.1002/mus.27385</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:1-19.</Citation></Reference><Reference><Citation>Arundine M, Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium. 2003;34:325-337.</Citation></Reference><Reference><Citation>Corona JC, Tapia R. AMPA receptor activation, but not the accumulation of endogenous extracellular glutamate, induces paralysis and motor neuron death in rat spinal cord in vivo. J Neurochem. 2004;89:988-997.</Citation></Reference><Reference><Citation>Kwak S, Hideyama T, Yamashita T, Aizawa H. AMPA receptor-mediated neuronal death in sporadic ALS. Neuropathology. 2010;30:182-188.</Citation></Reference><Reference><Citation>Van Den Bosch L, Vandenberghe W, Klaassen H, Van Houtte E, Robberecht W. Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons. J Neurol Sci. 2000;180:29-34.</Citation></Reference><Reference><Citation>Seeburg PH. The TiPS/TINS lecture: the molecular biology of mammalian glutamate receptor channels. Trends Pharmacol Sci. 1993;14:297-303.</Citation></Reference><Reference><Citation>Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004;27:723-749.</Citation></Reference><Reference><Citation>Netzahualcoyotzi C, Tapia R. Degeneration of spinal motor neurons by chronic AMPA-induced excitotoxicity in vivo and protection by energy substrates. Acta Neuropathol Commun. 2015;3:27.</Citation></Reference><Reference><Citation>Krauss GL, Bar M, Biton V, et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand. 2012;125:8-15.</Citation></Reference><Reference><Citation>Akamatsu M, Yamashita T, Hirose N, Teramoto S, Kwak S. The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci Rep. 2016;6:28649.</Citation></Reference><Reference><Citation>Pascuzzi RM, Shefner J, Chappell AS, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:266-271.</Citation></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293-299.</Citation></Reference><Reference><Citation>Paternostro-Sluga T, Grim-Stieger M, Posch M, et al. Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy. J Rehabil Med. 2008;40:665-671.</Citation></Reference><Reference><Citation>Posner K, Brown GK, Stanley B, et al. The Columbia-suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266-1277.</Citation></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169:13-21.</Citation></Reference><Reference><Citation>Bedlack R. ALSUntangled 48: perampanel (Fycompa). Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:453-456.</Citation></Reference><Reference><Citation>Oskarsson B, Mauricio EA, Shah JS, Zhuo L, Rogawski MA. Cortical excitability threshold can be increased by the AMPA blocker perampanel in ALS. Muscle Nerve. 2021;64:215-219.</Citation></Reference><Reference><Citation>Rugg-Gunn F. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia. 2014;55(suppl 1):13-15.</Citation></Reference><Reference><Citation>Lattanzi S, Grillo E, Brigo F, Silvestrini M. Efficacy and safety of perampanel in Parkinson's disease. A systematic review with meta-analysis. J Neurol. 2018;265:733-740.</Citation></Reference><Reference><Citation>Rabkin J, Goetz R, Murphy JM, Factor-Litvak P, Mitsumoto H, Group ACS. Cognitive impairment, behavioral impairment, depression, and wish to die in an ALS cohort. Neurology. 2016;87:1320-1328.</Citation></Reference><Reference><Citation>Lillo P, Mioshi E, Zoing MC, Kiernan MC, Hodges JR. How common are behavioural changes in amyotrophic lateral sclerosis? Amyotroph Lateral Scler. 2011;12:45-51.</Citation></Reference><Reference><Citation>Fang T, Jozsa F, Al-Chalabi A. Nonmotor symptoms in amyotrophic lateral sclerosis: a systematic review. Int Rev Neurobiol. 2017;134:1409-1441.</Citation></Reference><Reference><Citation>Chonan M, Saito R, Kanamori M, et al. Experience of low dose perampanel to add-on in glioma patients with levetiracetam-uncontrollable epilepsy. Neurol Med Chir (Tokyo). 2020;60:37-44.</Citation></Reference><Reference><Citation>Steinhoff BJ, Patten A, Williams B, Malhotra M. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: a pooled post hoc analysis of four randomized, double-blind, phase III studies. Epilepsia. 2020;61:278-286.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>